TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $15 from $13 and keeps a Buy rating on the shares. The firm said they posted good results and noted guidance was raised and still see room for upside.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies price target raised to $14 from $10 at JPMorgan
- Adaptive Biotechnologies Reports Strong Q2 2025 Growth
- Adaptive Biotechnologies: Strong Financial Performance and Strategic Initiatives Drive Optimistic Outlook
- Adaptive Biotechnologies reports Q2 EPS (17c), consensus (24c)
- COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake